Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.
Concurrent treatment with the methylating agent temozolomide during radiotherapy has yielded the first significant improvement in the survival of adult glioblastomas (GBM) in the last three decades. However, improved survival is observed in a minority of patients, most frequently those whose tumors display CpG methylation of the O(6)-methylguanine (O(6)-meG)-DNA methyltransferase (MGMT) promoter, and adult GBMs remain invariably fatal. Some, although not all, preclinical studies have shown that temozolomide can increase radiosensitivity in GBM cells that lack MGMT, the sole activity in human cells that removes O(6)-meG from DNA. Here, we systematically examined the temozolomide dose dependence of radiation killing in established GBM cell lines that differ in ability to remove O(6)-meG or tolerate its lethality. Our results show that minimally cytotoxic doses of temozolomide can produce dose-dependent radiosensitization in MGMT-deficient cells, MGMT-proficient cells, and MGMT-deficient cells that lack mismatch repair, a process that renders cells tolerant of the lethality of O(6)-meG. In cells that either possess or lack MGMT activity, radiosensitization requires exposure to temozolomide before but not after radiation and is accompanied by formation of double-strand breaks within 45 minutes of radiation. Moreover, suppressing alkyladenine-DNA glycosylase, the only activity in human cells that excises 3-methyladenine from DNA, reduces the temozolomide dose dependence of radiosensitization, indicating that radiosensitization is mediated by 3-methyladenine as well as by O(6)-meG. These results provide novel information on which to base further mechanistic study of radiosensitization by temozolomide in human GBM cells and to develop strategies to improve the outcome of concurrent temozolomide radiotherapy.
Bobola
Michael S
MS
Department of Neurological Surgery, University of Washington, Seattle, WA 98195-6470, USA.
Kolstoe
Douglas D
DD
Blank
A
A
Silber
John R
JR
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D001932:Brain Neoplasms / Q000235:genetics / Q000532:radiotherapy*; D053843:DNA Mismatch Repair / Q000187:drug effects / Q000235:genetics / Q000528:radiation effects; D015254:DNA Modification Methylases / Q000235:genetics* / Q000378:metabolism / Q000502:physiology; D045643:DNA Repair Enzymes / Q000235:genetics* / Q000378:metabolism / Q000502:physiology; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005720:Gamma Rays; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D005909:Glioblastoma / Q000235:genetics / Q000532:radiotherapy*; D006801:Humans; D020714:Maximum Tolerated Dose; D011836:Radiation Tolerance / Q000187:drug effects*; D000077204:Temozolomide; D014407:Tumor Cells, Cultured; D025521:Tumor Suppressor Proteins / Q000235:genetics* / Q000378:metabolism / Q000502:physiology
D000970:Antineoplastic Agents; D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide
PLoS Genet. 2009 Jan;5(1):e1000324
19119425
N Engl J Med. 2000 Nov 9;343(19):1350-4
11070098
J Cell Biochem. 2004 Feb 1;91(2):250-7
14743385
J Biol Chem. 2003 May 30;278(22):20303-12
12660252
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):612-20
17255284
DNA Repair (Amst). 2007 Aug 1;6(8):1079-99
17485253
Mol Cell. 2007 Nov 30;28(4):522-9
18042449
J Neurochem. 2006 Feb;96(3):766-76
16405512
Biochemistry. 2002 Jul 23;41(29):9248-55
12119040
Nat Rev Genet. 2006 Jan;7(1):45-54
16369571
J Neurooncol. 2003 Feb;61(3):203-7
12675312
Nat Chem Biol. 2009 Feb;5(2):82-90
19148176
Crit Rev Oncol Hematol. 2005 Mar;53(3):241-52
15718149
Nat Rev Cancer. 2008 Dec;8(12):957-67
19005492
Cancer Treat Rev. 2005 Dec;31(8):603-17
16298073
Chem Res Toxicol. 2006 Dec;19(12):1580-94
17173371
Br J Cancer. 1999 Nov;81(6):1022-30
10576660
DNA Repair (Amst). 2007 Jul 1;6(7):994-1003
17382606
Cancer Treat Rev. 1997 Jan;23(1):35-61
9189180
Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):779-84
10837964
Nat Clin Pract Neurol. 2005 Dec;1(2):88-95
16932504
J Biol Chem. 2004 May 7;279(19):20067-75
14982920
Annu Rev Genet. 2006;40:363-83
16895466
Clin Cancer Res. 1996 Apr;2(4):735-41
9816224
Pharmacol Res. 2007 Oct;56(4):275-87
17897837
Nat Clin Pract Oncol. 2008 Aug;5(8):476-86
18542116
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1246-53
17967314
Clin Cancer Res. 2004 Jun 1;10(11):3728-36
15173079
J Biol Chem. 1998 Feb 27;273(9):5412-8
9479003
Lancet Oncol. 2009 May;10(5):459-66
19269895
Clin Cancer Res. 2006 Aug 1;12(15):4738-46
16899625
Neurologist. 2006 Nov;12(6):279-92
17122724
J Biol Chem. 2006 Aug 11;281(32):22674-83
16772289
Radiat Res. 1995 Jun;142(3):362-8
7761586
Biochemistry. 1992 Sep 1;31(34):7998-8008
1510986
Clin Cancer Res. 2009 Jul 15;15(14):4622-9
19584161
Cell Cycle. 2008 Mar 15;7(6):796-807
18250621
DNA Repair (Amst). 2008 Nov 1;7(11):1776-86
18722555
Clin Cancer Res. 2008 Feb 1;14(3):931-8
18245557
DNA Repair (Amst). 2004 Jun 3;3(6):629-38
15135730
Clin Cancer Res. 2009 Jan 15;15(2):607-12
19147766
Mol Cancer Ther. 2005 Sep;4(9):1364-8
16170028
Nucleic Acids Res. 2008 Apr;36(7):2152-62
18281311
J Clin Oncol. 2008 Sep 1;26(25):4189-99
18757334
Clin Cancer Res. 2007 Apr 1;13(7):2038-45
17404084